SPA
CDLX icon

Sherbrooke Park Advisers’s Cardlytics CDLX Stock Holding History

Sherbrooke Park Advisers’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,826
Closed -$168K – 850
2023
Q4 		$168K Buy
+1,826
New +$186K 0.08% 351

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sherbrooke Park Advisers's CDLX Position: Q1 2024 in Review

Sherbrooke Park Advisers sold out of Cardlytics (CDLX) in Q1 2024, closing a stake of 1,826 shares — an estimated $168K sold.

Sherbrooke Park Advisers first reported a position in CDLX in Q4 2023 and held it in 1 quarter. The position peaked at $168K in Q4 2023. 144 funds tracked by Wall St. Rank hold CDLX as of Q1 2024.

  • Sherbrooke Park Advisers reported no remaining Cardlytics position as of Q1 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 1,826 Cardlytics shares in Q1 2024, an estimated $168K.
  • Sherbrooke Park Advisers first reported a position in Cardlytics in Q4 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Cardlytics position peaked at $168K in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Cardlytics as of Q1 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2024, filed 15 May 2024.